We are happy to give a presentation at ESTIV congress in Barcelona (21-25 November 2022)

Our Project Leader in in vitro pharmacology Méryl Roudaut will present his presentation entitled “A single procedure to generate functional hiPSCs-derived liver organoids – Towards an innovative tools suitable for drug screening” during the session: Early Stage Researcher Session I (Tuesday, November 22nd, 2022). Abstract #165: We previously showed that Read more…

Meet us at ESTIV congress in Barcelona (21-25 November 2022)

We are pleased to participate to the 21st International Congress of the European Society of Toxicology In Vitro (ESTIV 2022), which will take place in Barcelona-Sitges, Spain, from 21st to 25th November 2022. Our project Leader in in vitro pharmacology Véronique De Conto will present her poster entitled “In vitro microenvironment modifies the neurotoxic Read more…

Feedback of Natacha’s internship about the matrix remodeling in Parkinson’s disease: an in vitro study

This is the end of the 6-month internship of Natacha in HCS Pharma, about the microenvironment modifications in Parkinson’s disease. Indeed, in vivo studies in the literature showed that the neuronal death in Parkinson’s disease involved Extracellular Matrix (ECM) modifications, including an increase in some components like collagen and a Read more…

Feedback to the annual congress of the SCMC (Societe Cerveau et Maladies Cerebrovasculaires – Brain and cerebrovascular diseases Society)

Elodie Vandenhaute (our project director), Véronique De Conto (our project leader in in vitro pharmacology) and Natacha Perrin (our trainee in neurosciences) were present at the annual SCMC (Société Cerveau et Maladies Cérébrovasculaires – The French Brain and Cerebrovascular Diseases Society) congress, which took place on the 16th of June Read more…

Importance of the microenvironment in cerebral in vitro models for phenotypic screening (Abstract of Veronique’s thesis)

About 90% of drug candidates fail in clinical trials, for efficacy- and toxicity-related reasons, which often involve the Central Nervous System (CNS). This high failure rate highlights a lack of relevance in experimental models used upstream, including human in vitro models. Indeed, they do not take into account the complexity Read more…

We will present our researches on the importance of ECM for drug discovery in Parkinson’s disease at NeuroFrance congress (May 19 to 21 )

The international NeuroFrance congress will take place May, 19, 20 and 21th 2021 (virtual meeting). On this occasion, our PhD student Véronique De Conto will present these works in a poster about the importance of matricial and cellular microenvironment for drug discovery in Parkinson’s disease (summary below). Feel free to Read more…

Impact of neurodegenerative diseases on extracellular space organization and diffusion through hyaluronan remodeling

Soria et al. has published this year an interesting study about the modification leading by synucleopathy on the nanoscale organization and diffusivity of the extracellular space, through hyaluronan remodeling. Indeed the extracellular space (ECS), composed by the interstitial fluid and the extracellular matrix (ECM), plays several roles in health and Read more…

3D co-culture of dopaminergic neurons and astrocytes in BIOMIMESYS® Brain to study Parkinson’s disease

Parkinson’s disease affects more than 6 million people worldwide. This neurodegenerative disease is characterized by the death of dopaminergic neurons in the substantia nigra pars compacta, with intracellular accumulation of alpha-synuclein aggregates known as Lewi bodies. This neuronal loss leads to a decrease in the neurotransmitter dopamine that cause mainly Read more…